Isentress (Raltegravir)

Raltegravir blocks the HIV‑1 integrase enzyme, which is essential for inserting viral DNA into the host cell’s genome. By preventing this integration step, the drug stops the virus from establishing a permanent infection in cells, thereby reducing viral replication and disease progression.

The specific dose of Isentress is determined by the prescribing healthcare professional based on the patient’s age, weight, renal function, and the overall antiretroviral regimen. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Isentress is classified as pregnancy category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy if the benefits outweigh potential risks, and breastfeeding decisions should be made in consultation with a healthcare provider.

To order Isentress, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Isentress (raltegravir) is an earlier‑generation integrase strand transfer inhibitor, offering a well‑established safety profile and twice‑daily dosing. Newer agents such as dolutegravir provide once‑daily dosing and a higher barrier to resistance, but selection depends on individual patient factors, resistance patterns and clinician preference.

Isentress tablets should be stored at ambient temperature, below 25 °C, in their original blister pack to protect from moisture and light. Keep the medication out of reach of children and avoid storing in bathrooms or other humid environments.

Isentress is taken orally as a tablet, usually with or without food. The tablet should be swallowed whole with water and not crushed or chewed. Dosing times are typically spaced evenly throughout the day as directed by the prescriber.

Patients should be alert for signs of severe allergic reactions such as rash, blistering or mucosal involvement, which may indicate Stevens‑Johnson syndrome. Other serious concerns include liver toxicity (elevated liver enzymes) and muscle injury like rhabdomyolysis, which may present as unexplained muscle pain or weakness.

Isentress should be avoided in individuals with known hypersensitivity to raltegravir or any tablet excipients. It is also contraindicated when used with strong CYP3A inducers that markedly reduce drug exposure, and caution is advised in patients with severe hepatic impairment or those taking interacting medications.